A concerted appeal for international cooperation in preclinical stroke research

Stroke

Volumn 44, Issue 6, 2013, Pages 1754-1760

  Dirnagl, Ulrich ^a   Hakim, Antoine ^b   MacLeod, Malcolm ^c   Fisher, Marc ^d   Howells, David ^e   Alan, Stuart M ^f   Steinberg, Gary ^g   Planas, Anna ^h   Boltze, Johannes ^i,k   Savitz, Sean ^j   Iadecola, Costantino ^l   Meairs, Stephen ^m  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^l FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Cerebral ischemia; Roadblock; Translational medicine

Indexed keywords

ALTEPLASE; ENLIMOMAB; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FIBRINOLYTIC THERAPY; GENETIC ASSOCIATION; GENOTYPE; HEALTH CARE COST; HUMAN; MEDICAL SOCIETY; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; TISSUE REPAIR; TRANSLATIONAL RESEARCH;

CEREBRAL ISCHEMIA; ROADBLOCK; TRANSLATIONAL MEDICINE;

HUMANS; INTERNATIONAL COOPERATION; PHENOTYPE; STROKE; TRANSLATIONAL MEDICAL RESEARCH; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84880147654     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000734     Document Type: Article

References (67)

1. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3:90cm17.
2. UN. UN Resolution 66 l.1.2011. Available at http://www.un.org.en/ga/ president/65/issues/ncdiseases.shtml. Accessed January 18, 2013.
3. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397.
4. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
5. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198.
6. Mergenthaler P, Dirnagl U. Protective conditioning of the brain: expressway or roadblock? J Physiol. 2011;589:4147-4155.
7. Carmichael ST. Translating the frontiers of brain repair to treatments: starting not to break the rules. Neurobiol Dis. 2010;37:237-242.
8. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune defciency syndrome. Nat Rev Neurosci. 2005;6:775-786.
9. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9:105-118.
10. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334:197.
11. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7:e1000245.
12. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007;30:433-439.
13. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
14. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008;25:268-278.
15. Meairs S, Wahlgren N, Dirnagl U, Lindvall O, Rothwell P, Baron JC, et al. Stroke research priorities for the next decade-A representative view of the European scientifc community. Cerebrovasc Dis. 2006;22:75-82.
16. Stroke Progress Review Group. Final Report January 2012. National Institute of Neurological Disorders and Stroke web site. Available at http://www.ninds.nih.gov/find-people/groups/stroke-prg/01-2012-stroke-prg- report.htm. Accessed January 18, 2013.
17. Howells DW, Sena ES, O'Collins V, Macleod MR. Improving the effciency of the development of drugs for stroke. Int J Stroke. 2012;7:371-377.
18. Mathers CD, Loncar D. Updated projections of global mortality and burden of disease, 2002-2003: data sources, methods and results. 2005. World Health Organization web site. http://www.who.int/healthinfo/sta-tistics/ bodprojectionspaper.pdf. Accessed January 18, 2013.
19. Schumacher HC, Bateman BT, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med. 2007;50:99-107.
20. Stroke Unit Trialists' Collaboration. Organized inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2007;CD000197.
21. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478.
22. Vesterinen HM, Egan K, Deister A, Schlattmann P, Macleod MR, Dirnagl U. Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the Journal of Cerebral Blood Flow & Metabolism. J Cereb Blood Flow Metab. 2011;31:1064-1072.
23. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke. 1977;8:51-57.
24. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230:1289-1292.
25. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
26. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17:439-447.
27. Quartermain D, Li YS, Jonas S. Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke. Neurol Res. 2007;29:469-475.
28. Zhu H, Fan X, Yu Z, Liu J, Murata Y, Lu J, et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab. 2010;30:1137-1146.
29. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al.; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
30. Rosomoff HL. Hypothermia and cerebral vascular lesions. I. Experimental interruption of the middle cerebral artery during hypothermia. J Neurosurg. 1956;13:244-255.
31. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549-556.
32. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557-563.
33. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al.; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647-e656.
34. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasmino-gen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke. 2010;41:1008-1012.
35. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycopro-tein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330.
36. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, et al.; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
37. Gertz K, Laufs U, Lindauer U, Nickenig G, Böhm M, Dirnagl U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
38. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43:147-154.
39. Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke. 2001;32:2665-2674.
40. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the enlimomab acute stroke trial. Neurology. 2001;23:1428-1434.
41. Jönsson AC, Lindgren I, Norrving B, Lindgren A. Weight loss after stroke: a population-based study from the Lund Stroke Register. Stroke. 2008;39:918-923.
42. Scherbakov N, Dirnagl U, Doehner W. Body weight after stroke: lessons from the obesity paradox. Stroke. 2011;42:3646-3650.
43. Prass K, Meisel C, Höfich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodefciency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198:725-736.
44. Urra X, Obach V, Chamorro A. Stroke induced immunodepression syndrome: from bench to bedside. Curr Mol Med. 2009;9:195-202.
45. Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their infuence on infection after stroke. Stroke. 2008;39:237-241.
46. Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43:3161-3167.
47. Bras J, Guerreiro R, Hardy J. Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci. 2012;13:453-464.
48. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7:61-73.
49. Weber JE, Ebinger M, Rozanski M, Waldschmidt C, Wendt M, Winter B, et al.; STEMO-Consortium. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology. 2013;80:163-168.
50. Vivien D, Gauberti M, Montagne A, Defer G, Touzé E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab. 2011;31:2119-2134.
51. Medcalf RL. Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches. Curr Drug Targets. 2011;12:1772-1781.
52. Gralla J, Brekenfeld C, Mordasini P, Schroth G. Mechanical thromboly-sis and stenting in acute ischemic stroke. Stroke. 2012;43:280-285.
53. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet. 2011;377:1693-1702.
54. Floel A, Cohen LG. Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke. Neurobiol Dis. 2010;37:243-251.
55. del Zoppo GJ. The neurovascular unit in the setting of stroke. J Intern Med. 2010;267:156-171.
56. Zhang JH, Badaut J, Tang J, Obenaus A, Hartman R, Pearce WJ. The vascular neural network-a new paradigm in stroke pathophysiology. Nat Rev Neurol. 2012;8:711-716.
57. Anthony DC, Couch Y, Losey P, Evans MC. The systemic response to brain injury and disease. Brain Behav Immun. 2012;26:534-540.
58. Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401-410.
59. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, et al.; Berlin Stroke Register Investigators. Factors infuencing inhospital mortality and morbidity in patients treated on a stroke unit. Neurology. 2011;77:965-972.
60. Meisel C, Meisel A. Suppressing immunosuppression after stroke. N Engl J Med. 2011;365:2134-2136.
61. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identifcation of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol. 2012;74:230-240.
62. Leiva-Salinas C, Wintermark M. The future of stroke imaging: what we need and how to get to it. Stroke. 2010;41:S152-S153.
63. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al.; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250.
64. Bath PM, Macleod MR, Green AR. Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke. 2009;4:471-479.
65. Dirnagl U, Fisher M. International, multicenter randomized preclinical trials in translational stroke research: it's time to act. J Cereb Blood Flow Metab. 2012;32:933-935.
66. GAIN Collaborative Research Group. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet. 2007;39:1045-1051.
67. Richter SH, Garner JP, Zipser B, Lewejohann L, Sachser N, Touma C, et al. Effect of population heterogenization on the reproducibility of mouse behavior: a multi-laboratory study. PLoS One. 2011;6:e16461.